BidaskClub Lowers Atrion (ATRI) to Hold

BidaskClub cut shares of Atrion (NASDAQ:ATRI) from a buy rating to a hold rating in a research report report published on Friday morning.

Shares of ATRI opened at $682.18 on Friday. The firm has a market capitalization of $1.26 billion, a P/E ratio of 37.46 and a beta of 0.56. Atrion has a twelve month low of $516.85 and a twelve month high of $718.11.

Atrion (NASDAQ:ATRI) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported $4.70 earnings per share for the quarter. The business had revenue of $38.85 million for the quarter. Atrion had a return on equity of 17.99% and a net margin of 22.57%.

Institutional investors and hedge funds have recently modified their holdings of the stock. Spark Investment Management LLC raised its position in shares of Atrion by 120.2% in the 2nd quarter. Spark Investment Management LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $1,318,000 after buying an additional 1,201 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Atrion in the 2nd quarter worth $396,000. Royce & Associates LP raised its position in shares of Atrion by 0.5% in the 2nd quarter. Royce & Associates LP now owns 39,227 shares of the medical instruments supplier’s stock worth $23,513,000 after buying an additional 178 shares during the period. Strs Ohio raised its position in shares of Atrion by 7.7% in the 2nd quarter. Strs Ohio now owns 1,400 shares of the medical instruments supplier’s stock worth $839,000 after buying an additional 100 shares during the period. Finally, Pennsylvania Trust Co raised its position in shares of Atrion by 2.7% in the 2nd quarter. Pennsylvania Trust Co now owns 10,652 shares of the medical instruments supplier’s stock worth $6,385,000 after buying an additional 280 shares during the period. 62.30% of the stock is currently owned by institutional investors and hedge funds.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Story: Why do company’s buyback their stock?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply